Status:
NOT_YET_RECRUITING
Correlation Study of Serum HER 2 Against HER 2-ADC Drug Efficacy in HER 2 Low-expressing Breast Cancer
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Collaborating Sponsors:
Shenzhen New Industries Biomedical Engineering Co., Ltd.
Conditions:
HER 2 Low-expressing Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Breast cancer is one of the most common malignancies in women worldwide, with HER2-positive breast cancer accounting for about 15-20% of all breast cancer cases. HER2 (Human epidermal growth factor re...
Detailed Description
ADC drugs are a new type of targeted therapy. ADC drugs are composed of monoclonal antibodies, linkers and drug carriers, which bind to the target antigen on the surface of tumor cells through antibod...
Eligibility Criteria
Inclusion
- 1\. Subjects with pathologically confirmed breast cancer; 2. The therapeutic drugs are anti-HER2-ADC drugs; 3. No history of other tumors; 4. Age \> 18 years old; 5. Have relatively complete clinical case characteristics data.
Exclusion
- 1\. Male breast cancer subjects; 2. Suffering from other malignant neoplasms; 3. Subjects with incomplete clinical case characteristics.
Key Trial Info
Start Date :
July 4 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 4 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06492447
Start Date
July 4 2024
End Date
March 4 2026
Last Update
July 9 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.